#
Update: Molecular Markers of FSHD
May 8, 2026
Development of an animal model that recapitulates the progression of FSHD in humans, and possible activity of T & B Cells.
#
Report: Assessing biological activity and in vivo efficiency of the epigenetic activator, 3R-ON
May 8, 2026
Histone Therapeutics is making progress with 3R-ON technology.